Douleurs rhumatismales : les cannabinoïdes peuvent-ils les soulager ? Aude Lecrubier Medscape, 28 décembre 2016 https://francais.medscape.com/voirarticle/3602900 Alors que de nombreux patients atteints de pathologies rhumatologiques souffrent de douleurs chroniques et que le cannabis à usage thérapeutique semble connaître un véritable essor, notamment en Amérique du Nord, une méta-analyse du Dr Mary-Ann Fitzcharles (Rhumatologue, Université de McGill, Canada) et coll. rapporte des résultats décevants (voir aussi notre article). En l’état, les données de la littérature suggèrent que les cannabinoïdes ne présentent pas d’intérêt pour soulager les douleurs rhumatismales [1]. « Ce que montre cette méta-analyse, c’est que l’effet antalgique est très modeste. En outre, il y a une [...]
Lire la suiteThe Association between Cannabis Product Characteristics and Symptom Relief Sarah S. STITH, Jacob M. VIGIL, Franco BROCKELMAN, Keenan KEELING, Branden HALL Scientific Reports - Nature, 2019, 9, 2712. Published online 2019 Feb 25. doi: 10.1038/s41598-019-39462-1 PMCID: PMC6389973 PMID: 30804402 Abstract Federal barriers and logistical challenges have hindered measurement of the real time effects from the types of cannabis products used medically by millions of patients in vivo. Between 06/06/2016 and 03/05/2018, 3,341 people completed 19,910 self- administrated cannabis sessions using the mobile device software, ReleafApp to record: type of cannabis product (dried whole natural Cannabis flower, concentrate, edible, tincture, topical), combustion method (joint, pipe, vaporization), Cannabis [...]
Lire la suiteA protocol for the delivery of cannabidiol (CBD) and combined CBD and ∆9-tetrahydrocannabinol (THC) by vaporisation Nadia SOLOWIJ, Samantha J. BROYD, Hendrika H. Van HELL, Arno HAZEKAMP BMC Pharmacol Toxicol, 2014, 15, 58 Published online 2014 Oct 16. doi: 10.1186/2050-6511-15-58 PMCID: PMC4274767 PMID: 25319497 Abstract Background Significant interest has emerged in the therapeutic and interactive effects of different cannabinoids. Cannabidiol (CBD) has been shown to have anxiolytic and antipsychotic effects with high doses administered orally. We report a series of studies conducted to determine the vaporisation efficiency of high doses of CBD, alone and in combination with ∆9-tetrahydrocannabinol (THC), to achieve faster onset effects in experimental and clinical [...]
Lire la suiteProspects for the Use of Cannabinoids in Oncology and Palliative Care Practice: A Review of the Evidence. Tomasz DZIERZANOWSKI Cancers (Basel), 2019, 11, 2 Abstract There is an increased interest in the use of cannabinoids in the treatment of symptoms in cancer and palliative care patients. Their multimodal action, in spite of limited efficacy, may make them an attractive alternative, particularly in patients with multiple concomitant symptoms of mild and moderate intensity. There is evidence to indicate cannabis in the treatment of pain, spasticity, seizures, sleep disorders, nausea and vomiting, and Tourette syndrome. Although the effectiveness of cannabinoids is limited, it was confirmed in [...]
Lire la suiteReview article : The endocannabinoid system and its therapeutic exploitation in multiple sclerosis : Clues for other neuroinflammatory diseases Valerio Chiurchiù, Mario van der Stelt, Diego Centonzed, Mauro Maccarrone, Progress in Neurobiology, 2018, 160 , 82–100 © 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). A B S T R A C T Multiple sclerosis is the most common inflammatory demyelinating disease of the central nervous system, caused by an autoimmune response against myelin that eventually leads to progressive neurodegeneration and disability. Although the knowledge on its underlying neurobiological mechanisms has considerably improved, there is a [...]
Lire la suiteRegulatory Barriers to Research on Cannabis and Cannabinoids : A Proposed Path Forward Daniele Piomelli, Robert Solomon, Donald Abrams, Agnes Balla, Igor Grant, Thomas Marcotte, and John Yoder Cannabis and Cannabinoid Research, Volume 4, Number 1, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2019.0010 After a century of criminalization, the United States and other industrialized countries are experiencing a dramatic shift in their social and legal attitudes toward cannabis. As of January 2019, 10 states (including California) and the District of Columbia have legalized the plant and its products for both medical and adult recreational use, whereas 24 other states have decriminalized its use as medicine.1 [...]
Lire la suiteMedicinal Use of Synthetic Cannabinoids—a Mini Review P. Muralidhar Reddy, Nancy Maurya & Bharath Kumar Velmurugan Current Pharmacology Reports, 2019 https://doi.org/10.1007/s40495-018-0165-y Abstract Purpose of Review : This review gives an overview of the medicinal uses of synthetic cannabinoids and other related aspects on the basis of recent as well as earlier studies that the authors considered relevant to the context and scope of the review. Recent Findings Synthetic cannabinoids are laboratory synthesized products eliciting effects way more than their natural counterparts. These compounds are more potent in generating intoxicating effects and are also difficult to be detected in conventional screening tests. Their clinical side effects are also more pronounced than [...]
Lire la suiteLong-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US Tristan T. Sands, Shahryar Rahdari, Michael S. Oldham, Eduardo Caminha Nunes, Nicole Tilton & Maria Roberta Cilio CNS Drugs, 2018 DOI : 10.1007/s40263-018-0589-2 Abstract Background : Purified cannabidiol is a new antiepileptic drug that has recently been approved for use in patients with Lennox–Gastaut and Dravet syndromes, but most published studies have not extended beyond 12–16 weeks. Objective : The objective of this study was to evaluate the long-term safety, tolerability, and efficacy of cannabidiol in children with epilepsy. Methods : Patients aged 1–17 years with refractory epilepsy were enrolled in an open-label [...]
Lire la suiteNeuroprotection by cannabidiol and hypothermia in a piglet model of newborn hypoxic-ischemic brain damage Lorena Barataa, Luis Arruza, Maria-José Rodríguez, Esther Aleo, Eva Vierge, Enrique Criado, Elena Sobrino, Carlos Vargas, María Ceprián, Ana Gutiérrez-Rodríguez, William Hind, José Martínez-Orgado Neuropharmacology, 2018. https://doi.org/10.1016/j.neuropharm.2018.11.020 A B S T R A C T Objective : Hypothermia, the gold standard after a hypoxic-ischemic insult, is not beneficial in all treated newborns. Cannabidiol is neuroprotective in animal models of newborn hypoxic-ischemic encephalopathy. This study compared the relative efficacies of cannabidiol and hypothermia in newborn hypoxic-ischemic piglets and assessed whether addition of cannabidiol augments hypothermic neuroprotection. Methods : One day-old HI (carotid clamp and FiO2 10% for 20min) [...]
Lire la suiteCannabis‐based products for pediatric epilepsy : A systematic review Jesse Elliott, Deirdre DeJean, Tammy Clifford, Doug Coyle, Beth K. Potter, Becky Skidmore, Christine Alexander, Alexander E. Repetski, Vijay Shukla, Bláthnaid McCoy, George A. Wells, Epilepsia, 2018, 1-14. DOI: 10.1111/epi.14608 Summary Objective : To assess the benefits and harms of cannabis‐based products for pediatric epilepsy. Methods : We identified in this living systematic review randomized controlled trials (RCTs) and nonrandomized studies (NRSs) involving children with epilepsy treated with cannabis‐based products. We searched MEDLINE, Embase, PsycINFO, Cochrane Library, and gray literature (April 25, 2018). The primary outcome was seizure freedom; secondary outcomes were seizure frequency (total, ≥50% reduction), quality of life, sleep, status epilepticus, death, gastrointestinal adverse [...]
Lire la suite